This trial is being completed to learn about how Aquamin® affects gastrointestinal
permeability, or the control of material passing from inside the gastrointestinal tract
through the gut wall into the rest of the body, in people with ulcerative colitis (UC),
Irritable Bowel Syndrome with diarrhea (IBS-D), and in healthy individuals.